Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-823778 · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| BMS-823778 (2 mg) | ACTIVE_COMPARATOR | \+ metformin |
| BMS-823778 (10 mg) | ACTIVE_COMPARATOR | \+ metformin |
| BMS-823778 (20 mg) | ACTIVE_COMPARATOR | \+ metformin |
| Placebo | PLACEBO_COMPARATOR | \+ metformin |
| Panel 1: BMS-823778 or Placebo matching BMS-823778 | EXPERIMENTAL | Healthy Subjects |
| Panel 2: BMS-823778 or Placebo matching BMS-823778 | EXPERIMENTAL | Healthy Subjects |
| Panel 3: BMS-823778 or Placebo matching BMS-823778 | EXPERIMENTAL | Healthy Subjects |
| Panel 4: BMS-823778 or Placebo matching BMS-823778 | EXPERIMENTAL | Subjects with T2DM |
| Panel 5: BMS-823778 or Placebo matching BMS-823778 | EXPERIMENTAL | Subjects with T2DM |
| Name | Type | Description |
|---|---|---|
| BMS-823778 | DRUG | Capsules, Oral, 2 mg, once daily, 28 days |
| Placebo | DRUG | Capsules, Oral, 0 mg, once daily, 28 days |
| Metformin | DRUG | Capsules, Oral, ≥ 1500 mg, once daily, 28 days |
| Placebo matching with BMS-823778 | DRUG | Capsules, Oral, 0 mg, Once daily, 14 days |
Inclusion Criteria: * Type 2 diabetes mellitus * Drug naive or on stable metformin therapy * HbA1c 7-10% * FPG ≤ 240mg/dL Exclusion Criteria: * History of myocardial infarction, coronary angioplasty or bypass grafts, valvular disease or repair, unstable angina pectoris, transient ischemic attack,...
Top 7 of 10 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Enlicitide |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Lepodisiran, Muvalaplin |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE3 | Pelacarsen |
| NewAmsterdam Pharma Company N.V. | NAMS | 3 | PHASE3 | Obicetrapib |
| AstraZeneca PLC | AZN | 2 | PHASE2 | Rosuvastatin, AZD0780, AZD4954 |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE1 | ARO-DIMERPA |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX310 |
BMS-823778 is an investigational small molecule being studied for dyslipidemia and Type 2 Diabetes Mellitus. It has been evaluated in clinical trials involving patients with hypercholesterolemia and Type 2 Diabetes, as well as healthy volunteers. It is not approved for any indication and remains in clinical development.
BMS-823778 targets HSD11B1, also known as 11-beta-hydroxysteroid dehydrogenase type 1. It acts as an inhibitor of this enzyme. By inhibiting HSD11B1, the drug is designed to modulate cortisol metabolism, which is being explored for effects on lipid levels and glucose control in dyslipidemia and Type 2 Diabetes Mellitus.
BMS-823778 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company has sponsored the clinical trials evaluating the drug in dyslipidemia and Type 2 Diabetes Mellitus.
BMS-823778 is in Phase 2 clinical development. It has completed two Phase 2 trials and one Phase 1 trial. The drug is investigational and has not been approved by the FDA or any other regulatory agency for dyslipidemia or Type 2 Diabetes Mellitus.
BMS-823778 has been studied in completed trials including NCT01112423, a Phase 2 safety study in subjects with hypercholesterolemia, and NCT01111955, a Phase 2 safety study in subjects with Type 2 Diabetes. A Japanese Phase 1 multiple ascending dose study, NCT01515202, was also completed. No trials are currently active.